An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A company announced that three research chemicals—GW-501516, RAD-140, and MK-677—are now being sold together as a "research use only" product. The announcement comes from a press release service and appears to be aimed at labs or hobbyist researchers, not people looking for medicines. It’s essentially a commercial availability update, not a clinical trial result. These three substances are often grouped with "SARMs" (selective androgen receptor modulators) or related experimental compounds, but they are different in how they act. RAD-140 is a SARM candidate that was developed to mimic some effects of testosterone on muscle and bone while ideally avoiding other side effects. MK-677 (also called Ibutamoren) is not a SARM; it stimulates growth-hormone release by acting on a receptor that tells the body to make more growth hormone. GW-501516 (sometimes called Cardarine) was developed to affect metabolism and endurance by activating a different pathway entirely (PPAR-delta). None of these are approved medicines for general use. The announcement itself does not report new experiments on people. It’s a product launch saying these compounds are available for "research use only," which in industry terms means the supplier intends them for lab experiments, not for treating patients. That label also often indicates they have not been approved by regulators for human therapy. So the release tells us availability and positioning, not safety or effectiveness. It doesn’t supply data about how well they work in people, how big any effects are, or what side effects to expect. Why does this matter? These compounds have been of interest to athletes, bodybuilders, and some researchers because of potential effects on muscle, fat, and endurance. Making them more widely available may increase the number of small labs testing them or lead to more people attempting to obtain them outside formal medical channels. For the research community, wider availability can speed up basic science. For the public, it raises the chance that unregulated use could occur, with uncertain consequences. Important caveats: "Research use only" is not a safety guarantee. These compounds have not gone through the full regulatory process to prove they are safe and effective for routine medical use. Some, like GW-501516, have raised safety concerns in animal studies, and RAD-140 and MK-677 have limited human data and known side effects in some reports. People should not use research-grade chemicals on themselves. Pregnant people, people with chronic illnesses, and athletes subject to drug testing should be especially cautious. The press release does not replace clinical trials or regulatory review. Bottom line: A supplier is now selling three experimental compounds together for lab research, but this is a commercial availability note—not proof they are safe or effective for people.
Source: GlobeNewswire